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1707-41 The Randomized Aldactone Evaluation Study
(RALES): Parallel Dose Finding Trial
Bertram Pitt. RALES Investigators. Ann Arbor, MI
Aldactone (AL), an aldosterone (A) receptor antagonist, causes diuresis and
symptomatic improvement in patients with heart failure (HF) maintained on
an angiotensin converting enzyme-inhibitor (ACE-I). The effective dose and
safety of AL in patients with HF on an ACE-I and loop diuretic was determined
in a multicenter, randomized, double-blind study of placebo (P) In = 401: AL
12.5 mg In = 41), 25 mg (n = 45). 50 mg (n = 47) and 75 mg (n = 41) over
12 weeks. Left ventricular ejection fraction was :::35%; 80% males; mean
age 62 years; with 50% in NYHA Class II and 50% in III-IV The mean dose of
captopril was 62.0 mg, enalapril 14.3 mg and furosemide 73.9 mg Digitalis
and Potassium (K) supplements were given in approximately 80% and 30%
of patients, respectively. Efficacy was assessed by measuring changes in N-
terminal plasma atrial natriuretic factor(ANF) pmollL and systolic (S)/diastolic
10) blood pressure (BP) mmHg from baseline to 12 weeks (A). Safety by A in
serum K mmollL. creatinine (Crl JLmollL and incidence of hyperkalemia (HK)
:::6.0 mmol/L.
P A112.5 AL25 AL50 AL75 p
AANF +55 -287* -295 -351' -371'
llS/D BP +2.6/+1.9 -141-2.3 -4.8/-32' ~S9/-53' -761-5.3'
llK -0.1 +0.2' +04' +0.5' +0.6'
llCr 0 +0.1' +0.1 +0.2' +0.3'
HK(%) 0 2 7 11 12
"p < 0.05 vs. placebo; **significant treatment effect. p < 0.05
There were no deaths during the drug administration period of the study
and no significant changes in NYHA class among treatment groups. Thus,
in patients with HF on an ACE-I and loop diuretic, AL at a dose :::12.5 mg
is effective, with a dose response relationship to 75 mg. There was an in-
creased incidence of HK with AL :::50 mg. The effect of AL on hospitalization
and death will be determined in the RALES-Survival Trial.
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1707-51 Functional Correlates and Prognostic Importance of
Chronic Atrial Fibrillation in Patients with Dilated
Cardiomyopathy and CHF
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1707-61 Amiodarone Decreases Ability of Baseline
Ventricular Arrhythmia Severity to Predict Mortality
Ross D. Fletcher, Steve Singh, CHF-STAT Investigators. Veterans Affairs Washington,
DC
The Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-
STAT) entered 633 high risk patients (pts) with ejection fraction (EF) :::40%,
PVCs/hr::: 10 on 24 hour Holter recording and on active vasodilator therapy.
Pts were randomized to amiodarone or placebo. Despite marked ventricu-
lar arrhythmia suppression, overall mortality was the same for amiodarone
and placebo treated pts. An analysis to identify groups at risk based on fre-
quency or severity of ventricular arrhythmia at baseline for both placebo and
amiodarone is as follows:
Placebo Amiodarone
Ml Ml P
PVCs < 30!hr 4% 14%
> 30!hr 19% <0.002 19% NS (047)
PVCs < median* 11% 16%
> median 21% <0.0003 19% NS (054)
High EF. Low PVC' 11% 13%
High PVC 13% NS 14% NS (048)
Low EF. Low PVC' 14% 17%)
High PVC 28% <0.05 23%) NS (048)
VT :<:3 eventsl24hr 13% 16%
0::4 21% <0.003 20% NS (0.43)
'High, Low ~ >, <, median. EF (26%)& PVCs!hr (128)
Ml = first year mortality
While increased arrhythmia severity predicted increased mortality on
placebo, it did not in patients subsequently assigned to amiodarone treat-
ment. Amiodarone appears to counter the effect of increased arrhythmia
severity on mortality.
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1708-1 I Defect Size with IV Dipyridamole Tc-99m Sestamibi
SPECT Imaging Predicts Both Future Cardiac Events
and Other Cardiac Hospitalizations
Joseph R. McClellan, Steven D. Herman, Mark I. Travin, Rhonda M. Jenkins, Gary
V. Heller. Memorial Hospital and Roger Williams Hospital, Brown University, Providence,
RI, Hospital of the University ofPennsylvania, Phi/adelphIiJ, PA
Optimal management of patients with coronary artery disease requires iden-
tification of those at greatest risk of future adverse cardiac events. The rela-
tionship between defect size after IV dipyridamole with Tc-99m Sestamibi
SPECT imaging and cardiac events (death, MI) or need for other cardiac
hospitalizations for CHF, unstable angina (UA) or late revascularization (REV)
(>6 months after imaging) was evaluated in 512 pts followed for 12.8 ± 9.8
months. Defects were classified as small (Sml), moderate (Mod) or large
(Lrg). Of 216 pts with normal scans, there were 3 cardiac events and 11
other cardiac hospitalizations. Of the 296 pts with abnormal scans, there
were 22 cardiac events ISml 1.5%, Mod 6.9%, Lrg 12.5%) and 51 other car-
diac hospitalizations (SmI6%, Mod 12%, Lrg 20%). An abnormal scan was a
Prakash C. Deedwania, Steven Singh, Ross Fletcher, Susan Fisher, Bramah Singh,
CHF STAT Investigators. VAMCIFresno & Washington
Although atrial fibrillation (A. fib) has been labeled as a marker of relatively
advanced LV dysfunction and increased mortality in patients with CHF, the
available data provide conflicting findings. Accordingly, we evaluated the re-
lationship of chronic A. fib with several important clinical and objective pa-
rameters in the Congestive Heart Failure Survival Trial of Antiarrhythmic Ther-
apy (CHF STAT). A total of 633 patients with LVEF < 40%, dilated cardiomy-
opathy and chronic CHF were evaluated. Ninety-six percent were receiving
ACE inhibitors. Baseline characteristics: 97 (15%) had A. fib. Comparison of
baseline characteristics (mean values) between patients with A. fib (n = 971
and those without A. fib In = 536) is shown:
Mean Etiology LVEF LVIDd XRay Avg % on
Age IHD NIHD <30% >5Smm CT> 05 PVCslh Dig
A. fib (+) 65 ± 58% 42%* 63% 97% 98%* 228 96%"
A. fib(-) 67 ± 73%27% 66% 96% 84% 188 66%
, ~ P < 0.01
The analyses of above data showed that significantly greater number of
patients with CHF and A. fib had CT ratio > 0.5 on chest X-ray as well as
a larger percent of A. fib patients had non ischemic cardiomyopathy. As ex-
pected, a significantly greater proportion of A. fib patients were receiving
digoxin therapy.
Follow-up: All patients were followed on a regular basis at 3 mo intervals.
During the median follow-up period of 25 months, Kaplan-Meier survival es-
timates of the overall cardiac mortality and the risk of sudden cardiac death
did not reveal significant difference between patients with chronic atrial fib-
rillation and those without A. fibrillation.
Conclusion: These results demonstrate that in patients with dilated car-
diomyopathy, systolic LV dysfunction and chronic CHF, the presence of A.
fib is not a marker of more advanced heart failure nor an increased risk of
cardiac mortality and sudden cardiac death.
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